Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease

Myostatin is a negative regulator of skeletal muscle and has become a therapeutic target for muscle atrophying disorders. Although previous inhibitors of myostatin offered promising preclinical data, these therapies demonstrated a lack of specificity toward myostatin signaling and have shown limited...

Descripción completa

Detalles Bibliográficos
Autores principales: Welsh, Brian T., Cote, Shaun M., Meshulam, Deborah, Jackson, Justin, Pal, Ajai, Lansita, Janice, Kalra, Ashish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326894/
https://www.ncbi.nlm.nih.gov/pubmed/34255983
http://dx.doi.org/10.1177/10915818211025477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326894/
https://www.ncbi.nlm.nih.gov/pubmed/34255983
http://dx.doi.org/10.1177/10915818211025477

Ejemplares similares